BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 36362209)

  • 21. Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer.
    Ohar JA; Cheung M; Talarchek J; Howard SE; Howard TD; Hesdorffer M; Peng H; Rauscher FJ; Testa JR
    Cancer Res; 2016 Jan; 76(2):206-15. PubMed ID: 26719535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic landscape of pleural and peritoneal mesothelioma tumours.
    Hiltbrunner S; Fleischmann Z; Sokol ES; Zoche M; Felley-Bosco E; Curioni-Fontecedro A
    Br J Cancer; 2022 Nov; 127(11):1997-2005. PubMed ID: 36138075
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas.
    Sementino E; Menges CW; Kadariya Y; Peri S; Xu J; Liu Z; Wilkes RG; Cai KQ; Rauscher FJ; Klein-Szanto AJ; Testa JR
    J Cell Physiol; 2018 Nov; 233(11):8952-8961. PubMed ID: 29904909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignant Mesothelioma and Its Non-Asbestos Causes.
    Attanoos RL; Churg A; Galateau-Salle F; Gibbs AR; Roggli VL
    Arch Pathol Lab Med; 2018 Jun; 142(6):753-760. PubMed ID: 29480760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma.
    Sneddon S; Leon JS; Dick IM; Cadby G; Olsen N; Brims F; Allcock RJ; Moses EK; Melton PE; de Klerk N; Musk AW; Robinson BW; Creaney J
    Gene; 2015 May; 563(1):103-5. PubMed ID: 25796603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
    Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
    J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos Exposure.
    Dragon J; Thompson J; MacPherson M; Shukla A
    J Cell Biochem; 2015 Aug; 116(8):1540-52. PubMed ID: 25757056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.
    Borczuk AC; Pei J; Taub RN; Levy B; Nahum O; Chen J; Chen K; Testa JR
    Cancer Biol Ther; 2016; 17(3):328-35. PubMed ID: 26853494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
    Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
    Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.
    Andujar P; Lacourt A; Brochard P; Pairon JC; Jaurand MC; Jean D
    J Toxicol Environ Health B Crit Rev; 2016; 19(5-6):151-172. PubMed ID: 27705546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
    Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
    Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
    Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
    Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
    [No Abstract]   [Full Text] [Related]  

  • 33. Genomic Deletion of
    Sarun KH; Lee K; Williams M; Wright CM; Clarke CJ; Cheng NC; Takahashi K; Cheng YY
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma.
    Xu J; Kadariya Y; Cheung M; Pei J; Talarchek J; Sementino E; Tan Y; Menges CW; Cai KQ; Litwin S; Peng H; Karar J; Rauscher FJ; Testa JR
    Cancer Res; 2014 Aug; 74(16):4388-97. PubMed ID: 24928783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pleural mesothelioma.
    Porcel JM
    Med Clin (Barc); 2022 Sep; 159(5):240-247. PubMed ID: 35636988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
    Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
    Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
    [No Abstract]   [Full Text] [Related]  

  • 39. Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths.
    Nash A; Creaney J
    Curr Oncol Rep; 2023 Dec; 25(12):1515-1522. PubMed ID: 38015374
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.